Obstructive sleep apnea (OSA) is a chronic condition characterized by repetitive collapse of the upper airway during sleep leading to significant hypoxemia and recurrent arousals from sleep. It is a prevalent disorder particularly among middle-aged, obese men, although its existence in women, as well as in lean individuals, is increasingly recognized [1–5]. Four percent of adult men and 2% of adult women in general population random samples meet the current clinical and polysomnographic criteria for the diagnosis of sleep apnea warranting immediate therapeutic intervention [2–4]. A much larger group, 17% to 24% of men and 5% to 9% of women, demonstrate an apnea/hypopnea index of more than five events per hour of sleep [2–4], which was the originally proposed criterion for sleep apnea [6].

OSA is associated with considerable morbidity and mortality. Various studies indicate a causal relationship between OSA and hypertension, cardiovascular disease, and diabetes mellitus, independently of obesity [7]. Obesity is the most important reversible risk factor for OSA [8]. Furthermore, OSA is associated with excessive daytime sleepiness, which results in declines in quality of life [9] and increased risk for crashes while driving.
[10]. The first line of therapy is continuous positive airway pressure (CPAP) but its efficacy is limited, especially in mild to moderate OSA, and the compliance is poor [1,7].

In this article, we review knowledge accumulated during the past 10 years about sleep apnea and its association with the stress system, inflammation, insulin resistance, and visceral obesity.

**Sleep apnea and the stress system**

The hypothalamic-pituitary-adrenal (HPA) axis mediates the reaction to acute physical and psychological stress. HPA and sleep interact in multiple ways. Sleep, in particular deep sleep, has an inhibitory influence on the HPA axis [11], whereas activation of the HPA axis or administration of glucocorticoids can lead to arousal and sleepiness [12,13].

The sequence of events in OSA—breathing cessation, nocturnal hypoxia, continuous brief arousals, and sleep fragmentation —could activate both the systemic sympathetic/adrenomedullary and the HPA axis limbs of the stress system [14]. Nocturnal awakenings are associated with pulsatile cortisol release [15] and autonomic activation. Plasma and urinary catecholamines measured during the night-time, and surge of sympathetic nerve activity determined by microneurography, are elevated in patients with OSA compared with obese controls [16,17]. However, the limited existing literature has failed to detect any differences in plasma cortisol levels between sleep apneics and controls [18]. Most studies have focused on the effects of CPAP on cortisol with conflicting data [19–23]. Two studies have reported that CPAP does not reduce cortisol levels [19,20]. One study reported that acute withdrawal of CPAP therapy does not result in an increase in cortisol levels [22]. In contrast, another study reported that CPAP corrected preexisting hypocortisolemia, particularly after prolonged use [21]. In several of these studies cortisol was measured at a single time point and appropriate controls were not selected.

According to our unpublished data, cortisol levels were slightly higher in obese apneic patients, compared with obese controls, and both groups had lower plasma levels of cortisol compared with nonobese controls [24]. In the sleep apneic patients, CPAP lowered significantly diastolic and mean blood pressure (\(P < .05\)) and tended to reduce cortisol levels. In another study, corticotropin-releasing hormone (CRH) administration resulted in a higher corticotropin (ACTH) response in both obese apneic and nonapneic groups compared with nonobese controls, whereas there were no differences of cortisol response to CRH. These results suggest that in nondistressed obese individuals, HPA axis activity is rather low because of hyposecretion of hypothalamic CRH, whereas apnea causes a mild activation of the axis that is corrected with the use of CPAP.

**Sleep apnea and inflammation**

Proinflammatory cytokines, particularly interleukin (IL)-1 and tumor necrosis factor-alpha (TNF-\(\alpha\)), have been studied extensively in animal studies and have been found to meet the criteria of sleep regulating substances (for a thorough review see chapter by Dr. Krueger in this issue).

In healthy people the inflammatory cytokines TNF-\(\alpha\), IL-1\(\beta\), and IL-6 are involved in physiological sleep regulation with a circadian pattern of secretion [25–28]. Decreased overall secretion of IL-6 is associated with a good night’s sleep and a good sense of well-being the next day [27]. Increased secretion or exogenous administration of IL-6 to humans is associated with excessive daytime sleepiness (EDS) and fatigue [29]. EDS occurs in about 5% to 10% of the general population [30,31] and is the chief complaint of the majority of patients evaluated in sleep disorders centers. EDS is one of the major physiological consequences of OSA.

We evaluated cytokine levels in three patient populations with EDS: sleep apneics (\(n = 12\)), narcoleptics (\(n = 11\)) and idiopathic hyporsomniacs (\(n = 8\)) [32]. TNF-\(\alpha\) was significantly elevated in sleep apneics and narcoleptics and IL-6 was elevated only in sleep apneics (Fig. 1). Both TNF-\(\alpha\) and IL-6 plasma concentrations were positively correlated with the presence of EDS. Furthermore, TNF-\(\alpha\) was positively correlated with the degree of nocturnal sleep disturbance, and the degree of hypoxia, whereas IL-6 was positively correlated with the degree of nocturnal sleep disturbance, degree of hypoxia, and body mass index (BMI).

In a new study that we controlled for obesity, the sleep apneic men had higher plasma concentrations of TNF-\(\alpha\), IL-6, and leptin than nonapneic obese men who had intermediate values or lean men who had the lowest values [33]. These findings suggested that TNF-\(\alpha\) and IL-6 were elevated in sleep apnea independently of obesity. BMI correlated positively with both cytokines and leptin.

IL-6 induces C-reactive protein (CRP) production [34]. CRP is a biomarker of low-grade systemic inflammation, which plays an important role in arterial plaque formation, plaque rupture, and vascular thrombosis thereby increasing the susceptibility to myocardial ischemia and infarction [35]. Low-grade systemic inflammation may be a possible mechanism linking OSA to cardiovascular disease. Prior studies examining the association between OSA and CRP levels have produced conflicting
results, with some studies verifying an independent association with disease severity [36–45] and others showing no relationship [46–51]. Potential limitations of previous work are the confounding effects of obesity and medical comorbidity. A recent, well-designed study demonstrated that, in the absence of confounding medical conditions, sleep-disordered breathing (SDB) was associated with elevated levels of CRP with a dose-response relationship, independent of age, BMI, waist circumference, and percent body fat, suggesting that a state of low-grade inflammation is present in SDB and may act as an intermediary in the causal pathway to cardiovascular disease [52].

Sleep apnea and leptin

Leptin is an adipocyte-derived hormone that regulates body weight through control of appetite and energy expenditure [53]. Leptin levels correlate with BMI and insulin levels, and its secretion is further modulated by the stress system and cytokines [53].

Several studies have shown that sleep apnea is associated with hyperleptinemia that correlates to insulin levels [33,54–56]. In studies that included primarily obese patients, the higher levels of leptin have been accounted for by obesity and/or excessive visceral fat [33], whereas in others that included primarily nonobese patients, elevated leptin levels were reported independently of obesity.

In our study, apnea/hypopnea index (AHI) did not make an additional contribution to leptin levels, and we suggested that the increase in leptin levels in sleep apnea may be related to the higher amount of visceral fat and/or cytokines [33]. Leptin levels were relatively higher in sleep apneics compared with normal weight controls when measured at two time periods. Further research with serial 24-hour sampling is needed to evaluate if sleep apnea is associated with a change of the circadian secretion of leptin [33,56].

Sleep apnea and insulin resistance

Because of the association between inflammation and insulin resistance, a condition of increased insulin levels associated with normoglycemia (for detailed description see article by Drs. Aurora and Punjabi in this issue), we examined whether OSA acts as an independent risk factor for insulin resistance. We evaluated 14 obese men with symptomatic sleep apnea versus 11 BMI- and age-matched, obese, nonapneic controls [33]. Mean fasting blood glucose levels were higher in the apneics than in obese controls (106.2 ± 4.1 versus 85.4 ± 4.4, \( P < .01 \)). Mean plasma insulin levels were also higher in sleep apneics than in obese controls (25.7 ± 4.2 versus 14.6 ± 2.5, \( P < .05 \)).

Our findings were confirmed by three relatively large studies: (1) a sleep center population in Hong Kong [57], (2) a community-based sample in the Baltimore area [58], and (3) most recently in a large sample from the Sleep Heart Health Study [59]. Importantly, one study observed that the association between OSA and insulin resistance was present even in nonobese subjects [57], whereas the study in the Baltimore area reported insulin resistance even in mild forms of sleep apnea [58].

Previous studies reported inconsistent results in terms of an association between sleep apnea and insulin resistance. A large study showed a modest relation (\( r^2 = 0.10 \)) between the AHI and fasting insulin levels, but not fasting blood glucose levels [60]. Two other studies showed an association between severity of sleep apnea and indices of insulin resistance [61] and that sleep apnea occurred commonly in obese patients with diabetes type 2 who
had excessive daytime sleepiness or heavy snoring [62]. In contrast, two other controlled studies suggested that the relation between sleep apnea and plasma insulin levels [63] or insulin resistance [64] reflected the known effects of obesity. However, in one of these studies, the apneics were otherwise healthy normotensive individuals [64], whereas in the second study, the apneics were lean and less symptomatic [63]. The weak correlations between sleep apnea and insulin levels in clinical samples and the absence of insulin resistance in otherwise asymptomatic apneics reported in some studies may be due to the possibility that sleep apnea is a heterogeneous disorder in terms of its association with insulin resistance and/or that sleep apnea without symptoms has a weak association with insulin resistance.

**Sleep apnea and visceral fat**

Visceral fat is closely associated with insulin resistance and insulin resistance is associated with sleep apnea independent of obesity. Waist circumference is a better predictor of OSA than BMI [65]. In a study we examined whether sleep apnea correlates with visceral, subcutaneous (SC), or total fat by using CT scanning to assess body fat distribution [33]. Male patients with OSA had a greater amount of CT-determined visceral adipose tissue into the abdomen than a group of BMI-matched men without SDB ($P < .05$). Interestingly, BMI correlated significantly with total body fat (measured at L3: $r_{xy} = 0.83; P < .01$) and SC fat ($r = 0.88; P < .01$), but not with visceral fat. Importantly, visceral, but not SC fat, was significantly correlated with indices of sleep apnea ($r_{xy} = 0.70; P < .01$ for AHI and $r_{xy} = -0.60; P < .01$ for minimum SaO2) (Fig. 2). Our findings are consistent with reports that visceral fat accumulation is an important risk factor for OSA in obese subjects [66], and the AHI is significantly correlated with intra-abdominal fat but not with SC fat in the neck region or parapharyngeal fat [67].

According to these results, we proposed that visceral obesity and insulin resistance determined by both genetic and environmental factors progressively leads to worsening metabolic syndrome manifestations and sleep apnea [33]. Progressive deterioration of sleep apnea may then accelerate the worsening of visceral obesity and the metabolic syndrome by providing a stress stimulus and causing nocturnal elevations of hormones, such as cortisol and insulin, that promote visceral adiposity, metabolic abnormalities, and cardiovascular complications [33,68] (Fig. 3). One other factor may be the sleep loss experienced by these patients, as this has recently been found to increase insulin resistance in normal subjects [69].

**Sleep apnea in disorders characterized by insulin resistance as the primary pathophysiologic mechanism**

If sleep apnea is associated with insulin resistance independently of obesity, then sleep apnea should be more prevalent in disorders in which insulin resistance is a primary abnormality, such as the polycystic ovary syndrome (PCOS) [70].

In collaboration with the Department of Obstetrics and Gynecology at Hershey Medical Center, we conducted a study that included 53 women with PCOS and 452 premenopausal women as controls [71]. The diagnosis of PCOS was made by the presence of chronic anovulation (six or fewer menstrual periods per year) in association with elevated circulating androgen levels [70]. Obstructive sleep apnea was diagnosed using Sleep Disorders Clinic criteria, which employed sleep laboratory (AHI $\geq 10$) plus clinical findings [3,4]. PCOS women were 30 times more likely to suffer from SDB than controls (odds ratio $[OR] = 30.6; 95\%$ confidence interval $[CI] = 7.2, 139.4; P < .001$). Even when we controlled for BMI, the difference between the two groups remained significant. Potential predictive factors, such as age, BMI, free and total testosterone,
Fasting insulin levels and glucose to insulin ratio were included in a logistic regression analysis. The backward conditional analysis eliminated all variables but insulin and glucose-to-insulin ratio, suggesting that insulin resistance was a stronger predictor for sleep apnea than age, BMI, or testosterone.

In a new study, we evaluated 42 obese women with PCOS, 17 BMI-comparable obese controls, and 15 normal-weight controls free from apnea for single morning cytokine plasma concentrations and insulin resistance indices [72]. Women with PCOS exhibited higher plasma concentrations of IL-6 than obese controls, who had intermediate values, or normal-weight controls, who had the lowest values (4.75 ± 0.5 versus 3.65 ± 0.4 versus 1.84 ± 0.3 pg/mL, P < .01) (Fig. 4). TNF-α values were higher in PCOS and obese controls compared with normal-weight controls, but the difference was not statistically significant. Based on backward regression analysis, IL-6 levels had a stronger association with the PCOS group than with the obese group, and the sleep or hypoxia variables did not make a significant contribution to either IL-6 or TNF-α. Both IL-6 and TNF-α correlated positively with BMI (P < .01) in obese controls but not in women with PCOS. Within the PCOS group, IL-6 and TNF-α correlated more strongly with indices of insulin resistance than obesity.

Our findings on the association of PCOS and OSA were confirmed in three other studies [73–75], suggesting that visceral obesity and insulin resistance, which is frequently associated with PCOS [70], is a primary pathogenetic mechanism leading to sleep apnea [76].
postmenopausal women on hormone therapy (HT) [4], and the presence of sleep apnea appears to be associated exclusively with obesity (BMI > 32.3%). Postmenopausal women without HT have a prevalence of sleep apnea that is close, although still lower, to the prevalence in men.

Loss of estrogen after menopause is associated with elevated IL-6, and with an increase in obesity (primarily central) and cardiovascular diseases [77]. It is possible that the elevations of inflammatory cytokines, central obesity, and/or insulin resistance are risk factors for increased prevalence of OSA and cardiovascular disease in postmenopausal women. In a recent study from the Women’s Health Initiative Hormone Trial, estrogen plus progestin decreased diabetes and insulin resistance in postmenopausal women, which might be a mechanism through which HT protects women from sleep apnea [78]. Furthermore, the adverse effect of menopause and the protective role of gonadal hormones in sleep apnea in women was confirmed in the Sleep Heart Health Study as well as in a Wisconsin cohort [79,80].

Sleep apnea and diabetes

Several studies have shown an increased prevalence of sleep apnea and SDB in patients with diabetes mellitus type 2 [62,81]. Mondini and Guilleminault [82] reported increased frequency of abnormal breathing during sleep in lean and obese diabetics. Brooks and colleagues [62] demonstrated that 70% of obese diabetics had moderate or severe OSA. In a Chinese population with OSA, diabetes mellitus was the second most common medical condition (about 10%) next to hypertension, associated with sleep apnea [83]. Two large prospective studies, one from Sweden and the other from the United States (Nurses’ Health Study Cohort), showed that regular snoring is associated with a two- to sevenfold risk for type 2 diabetes over a 10-year period [84,85]. These studies collectively suggest that diabetes is associated with OSA and, along with hypertension, should be added to the signs and symptoms of this prevalent sleep disorder (for a more extensive review of the issue, see the article by Drs. Aurora and Punjabi elsewhere in this issue).

Age distribution of sleep apnea and metabolic syndrome

Large epidemiologic studies have shown that the prevalence of significant apneic activity as measured in the sleep laboratory largely not associated with clinical symptoms (nonsymptomatic apnea) is much higher than that of sleep apnea based on the presence of both sleep laboratory and clinical findings (symptomatic apnea) [2–4]. According to these data, researchers propose that there are at least two different types of apnea [3,86]. The first type of apnea has an age-related distribution with a peak around age 55 years for men and 65 years for women and accounts for the symptomatic apnea, and the second type occurs primarily in the elderly and has not the clinical consequences of the first type.

The age distribution of symptomatic sleep apnea is similar to the age distribution of the metabolic syndrome [87]. Specifically, in a study on the prevalence of the metabolic syndrome in the US population from the Third National Health and Nutrition Examination Survey 1988–1994, it was demonstrated that the prevalence of the metabolic syndrome that is closely linked to insulin resistance rose with age, reached peak levels between ages 50 and 70, and then declined. Also, menopause increased the risk for metabolic syndrome in women. The similarities in age distribution between symptomatic sleep apnea and metabolic syndrome support our proposal that insulin resistance and visceral adiposity are more strongly linked to symptomatic apnea.

Sleep apnea and continuous positive airway pressure (CPAP) treatment

CPAP is the treatment of choice, especially in moderate to severe OSA, with proven efficacy on daytime sleepiness and high blood pressure [88,89]. Randomized trials have shown benefit in severe OSA in subjective sleepiness, objective tests of sleepiness, quality of life, driving performance, and depression scores [88]. On the other hand, no benefits of therapy were observed in severe OSA if subjects were not sleepy [90]. In mild to moderate disease, CPAP ameliorated only night-time symptoms (eg, snoring) in all studies [91–95], whereas in most studies subjective sleepiness did not change [92,94,95].

The effects of CPAP on the metabolic alterations associated with OSA have not been studied systematically, and the results are inconsistent [33,96]. No improvement in insulin sensitivity was observed in nine studies. The beneficial effect confirmed in one study was observed primarily in nonobese patients with OSA [97]. Also, in nonobese patients with OSA, visceral fat decreased after 6 months of CPAP use, even without change in BMI [98]. Also inconsistent were the results on the effects of CPAP on inflammation. A significant decrease in TNF-α was reported after the use of CPAP [99,100]. IL-6 increased in one study [101] and decreased in another study after the use of CPAP [38].
Studies to date have primarily evaluated short-term outcomes of CPAP use, typically 1 to 2 months, in both obese and nonobese patients with OSA.

According to our unpublished data, the therapeutic use of CPAP for 3 months, although its use ameliorated blood pressure and objective and subjective sleepiness, did not improve low-grade inflammation, insulin resistance, or visceral adiposity in obese men with severe sleep apnea. From the studies reviewed, it appears that CPAP has no effect on insulin resistance, inflammation, or visceral obesity in obese apneics. Besides methodological limitations inherent in human studies, the differential response of obese versus nonobese apneics to CPAP may suggest that the two groups of apneics are different in terms of the underlying pathophysiology and symptom profile. Indeed, nonobese apneics are characterized by less daytime sleepiness and more frequent presence of anatomic abnormalities than obese apneics [31,102]. In turn, the metabolic/inflammatory aberrations in obese apneics may be primary to the pathogenesis of apnea, whereas in the nonobese they may be secondary phenomena to the apnea per se. From a clinical standpoint, current evidence suggests that additional therapeutic measures, eg, weight loss, exercise, pharmacological agents such as antibodies that neutralize cytokines, and drugs that improve insulin sensitivity and reduce visceral fat, should be included in the management of sleep apnea.

The role of diet, exercise, and cytokine antagonists in the management of sleep apnea

Even modest weight loss results in a clinically significant improvement of metabolic complications and cardiovascular risk profile of obesity, which are closely associated with OSA [103]. Weight loss in surgically treated morbidly obese patients improved the symptoms of OSA [104] and reduced AHI [105]. In patients with OSA and severe visceral obesity (baseline BMI of 54.7 ± 9.5 kg/m²), treatment with intragastric balloon reduced the number of apneic episodes during sleep and the daytime symptoms of OSA, even with a relatively modest level of weight loss and despite the fact the patients still remained affected by severe obesity after treatment [106]. The improvements of OSA observed after a modest weight loss may be a part of the better responsiveness of visceral than subcutaneous fat to caloric restriction [107].

In a recent study in 1104 men and women enrolled in the Wisconsin Sleep Cohort Study, 7 hours or more of exercise per week compared with 0 hours of exercise per week was associated with a significant reduction of AHI (5.3 versus 2.8) independent of BMI, age, gender, and other covariates [108]. According to our unpublished data, among sleep apneics regular exercise is the strongest predictor of EDS in men, whereas depression, metabolic syndrome, and AHI are the strongest predictors of EDS in women. Exercise improves insulin resistance and visceral adiposity independently of body weight and this can be the mechanism positively affecting nighttime and daytime symptoms of OSA.

Finally, to test our hypothesis that the pro-inflammatory cytokines TNF-α and IL-6 are mediators of excessive daytime sleepiness in humans, we proceeded with a pilot study during which we administered etanercept, a medication that neutralizes TNF-α, or placebo in eight male, obese apneics [109]. There was a significant and marked decrease of sleepiness by etanercept, which increased sleep latency during the multiple sleep latency test (MSLT) by about 3.1 minutes compared with placebo. Also, the number of apneas/hypopneas per hour was reduced significantly by the drug compared with placebo (52.8 ± 9.1 versus 44.3 ± 10.3; adjusted difference—8.4 ± 2.3; P < .05) (Fig. 5). We concluded that neutralizing TNF-α activity is associated with a significant reduction of objective sleepiness in obese patients with OSA and that this effect suggests that pro-inflammatory cytokines contribute to the pathogenesis of OSA and sleepiness.

References


Fig. 5. Sleep latencies during daytime testing with MSLT in the placebo (■) and etanercept (○) conditions. Each data point represents the mean ± SE, P < .05, adjusted change between placebo and etanercept.


[61] Tiitinen M, Partinen M, Närvänen S. The severity of obstructive sleep apnoea is associated


